{"id":"urokinase-thrombolysis","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Hemorrhage"},{"rate":"1-5%","effect":"Allergic reactions"},{"rate":"1-5%","effect":"Fever"},{"rate":"1-5%","effect":"Nausea and vomiting"}]},"_chembl":{"chemblId":"CHEMBL1201420","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process involves the conversion of plasminogen to plasmin, which then degrades fibrin clots. Urokinase is a type of tissue plasminogen activator (tPA) that plays a crucial role in the fibrinolytic pathway. By activating plasminogen, urokinase helps to dissolve blood clots and restore blood flow.","oneSentence":"Urokinase thrombolysis works by activating plasminogen to plasmin, which breaks down blood clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:09.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT07187687","phase":"NA","title":"TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-10-24","conditions":"Intracerebral Hemorrhage","enrollment":750},{"nctId":"NCT07047326","phase":"NA","title":"Urokinase for Thrombolysis in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-10-01","conditions":"Acute Ischemic Stroke","enrollment":24},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT06833827","phase":"NA","title":"'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-02","conditions":"Pulmonary Embolism Acute","enrollment":111},{"nctId":"NCT06236828","phase":"","title":"The MRI-based Evaluation of Safety and Efficacy of EVT and SMT: A Retrospective, Multicenter Study","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-01-31","conditions":"Stroke, Acute Ischemic Stroke, Ischemic Stroke","enrollment":200},{"nctId":"NCT04516993","phase":"PHASE2","title":"CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2021-09-28","conditions":"Stroke","enrollment":224},{"nctId":"NCT04420351","phase":"PHASE3","title":"Thrombolysis of Urokinase for Minor Stroke","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2020-10-04","conditions":"Minor Stroke","enrollment":1005},{"nctId":"NCT01108120","phase":"PHASE2","title":"The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Xiang Guang-da","startDate":"2010-05","conditions":"Diabetic Foot Ulcer","enrollment":200},{"nctId":"NCT04256473","phase":"PHASE2","title":"Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2019-08-10","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT05117684","phase":"","title":"To Compare \"Balloon Occluded Thrombolysis\" With \"Conventional Catheter Directed Thrombolysis\" in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome.","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2021-11-05","conditions":"Budd-Chiari Syndrome","enrollment":33},{"nctId":"NCT01694381","phase":"EARLY_PHASE1","title":"Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor","status":"TERMINATED","sponsor":"TSI, LLC","startDate":"2012-09","conditions":"Acute Ischemic Stroke","enrollment":8},{"nctId":"NCT04688879","phase":"","title":"Thrombolysis With Intra-arterial Urokinase","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2020-03-01","conditions":"Arterial Occlusion Mesenteric Artery Superior","enrollment":13},{"nctId":"NCT03886194","phase":"NA","title":"Thrombolytic and Interventional Treatment of Pulmonary Embolism","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2019-08-18","conditions":"Pulmonary Embolism","enrollment":40},{"nctId":"NCT03578822","phase":"PHASE3","title":"Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-08-10","conditions":"Acute Ischaemic Stroke","enrollment":149},{"nctId":"NCT02854592","phase":"","title":"Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2017-04-01","conditions":"Ischemic Stroke","enrollment":4000},{"nctId":"NCT03997292","phase":"","title":"Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China","status":"WITHDRAWN","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-03-01","conditions":"Ischemic Stroke","enrollment":""},{"nctId":"NCT03388892","phase":"NA","title":"Drug-Eluting Balloon in Arteriovenous Graft","status":"COMPLETED","sponsor":"National Taiwan University Hospital Hsin-Chu Branch","startDate":"2015-01-29","conditions":"Kidney Failure, Chronic, Angioplasty, Dialysis","enrollment":44},{"nctId":"NCT01717755","phase":"NA","title":"Basilar Artery International Cooperation Study","status":"UNKNOWN","sponsor":"Erik van der Hoeven","startDate":"2011-10","conditions":"Basilar Artery Thrombosis, Basilar Artery Embolism, Stroke of Basilar Artery","enrollment":282},{"nctId":"NCT01204333","phase":"PHASE2, PHASE3","title":"Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis","status":"TERMINATED","sponsor":"Jan Stam, MD, PhD","startDate":"2011-09","conditions":"Sinus Thrombosis, Intracranial","enrollment":67},{"nctId":"NCT02414802","phase":"NA","title":"Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2014-12","conditions":"Venous Thrombosis","enrollment":40},{"nctId":"NCT02770560","phase":"","title":"Efficacy of Urokinase Containing Locking Solutions for Thrombotic Dysfunction of Tunneled Hemodialysis Catheters","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2010-05","conditions":"Kidney Failure, Chronic, Vascular Access Devices","enrollment":148},{"nctId":"NCT00811538","phase":"","title":"Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2007-12","conditions":"Ischemic Stroke","enrollment":1476},{"nctId":"NCT02088346","phase":"","title":"Acute Stroke Advancing Program Using Telemedicine","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2014-08","conditions":"Stroke","enrollment":300},{"nctId":"NCT01134237","phase":"PHASE3","title":"Intrapleural Urokinase for Retained Hemothorax","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-05","conditions":"Retained Hemothorax","enrollment":32},{"nctId":"NCT00968929","phase":"PHASE4","title":"Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2006-06","conditions":"Pulmonary Embolism, Pulmonary Thromboembolism","enrollment":83},{"nctId":"NCT00799968","phase":"PHASE4","title":"12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2002-06","conditions":"Pulmonary Embolism, Thromboembolism","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":94,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Urokinase"],"phase":"phase_3","status":"active","brandName":"Urokinase thrombolysis","genericName":"Urokinase thrombolysis","companyName":"Capital Medical University","companyId":"capital-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Urokinase is an exogenous protein used as a thrombolytic agent, specifically targeting the enzyme Urokinase-type plasminogen activator. It is studied for use in treating conditions such as ischemic stroke, pulmonary embolism, and basilar artery thrombosis or embolism, often in conjunction with other interventions like catheter-directed thrombectomy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}